JP2014505108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505108A5 JP2014505108A5 JP2013553575A JP2013553575A JP2014505108A5 JP 2014505108 A5 JP2014505108 A5 JP 2014505108A5 JP 2013553575 A JP2013553575 A JP 2013553575A JP 2013553575 A JP2013553575 A JP 2013553575A JP 2014505108 A5 JP2014505108 A5 JP 2014505108A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- pharmaceutically acceptable
- acceptable salt
- hydrate
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims description 163
- 239000012453 solvate Substances 0.000 claims description 142
- 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 claims description 73
- 239000003112 inhibitor Substances 0.000 claims description 70
- 208000010877 cognitive disease Diseases 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 50
- 229960004002 levetiracetam Drugs 0.000 claims description 33
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 33
- 210000003169 central nervous system Anatomy 0.000 claims description 30
- 208000028698 Cognitive impairment Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 229960002161 brivaracetam Drugs 0.000 claims description 27
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 claims description 27
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 27
- 229940102566 valproate Drugs 0.000 claims description 27
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 claims description 19
- 229950000852 seletracetam Drugs 0.000 claims description 19
- 230000006999 cognitive decline Effects 0.000 claims description 15
- 208000015114 central nervous system disease Diseases 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 22
- 230000003920 cognitive function Effects 0.000 claims 11
- 150000004677 hydrates Chemical class 0.000 claims 9
- 238000013265 extended release Methods 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000001149 cognitive effect Effects 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 95
- 239000008194 pharmaceutical composition Substances 0.000 description 11
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441251P | 2011-02-09 | 2011-02-09 | |
| US61/441,251 | 2011-02-09 | ||
| PCT/US2012/024556 WO2012109491A1 (en) | 2011-02-09 | 2012-02-09 | Methods and compositions for improving cognitive function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016132218A Division JP2016172772A (ja) | 2011-02-09 | 2016-07-04 | 認知機能を改善するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014505108A JP2014505108A (ja) | 2014-02-27 |
| JP2014505108A5 true JP2014505108A5 (https=) | 2015-04-02 |
Family
ID=46638963
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553575A Withdrawn JP2014505108A (ja) | 2011-02-09 | 2012-02-09 | 認知機能を改善するための方法および組成物 |
| JP2016132218A Withdrawn JP2016172772A (ja) | 2011-02-09 | 2016-07-04 | 認知機能を改善するための方法および組成物 |
| JP2018060195A Withdrawn JP2018100305A (ja) | 2011-02-09 | 2018-03-27 | 認知機能を改善するための方法および組成物 |
| JP2020033698A Pending JP2020079318A (ja) | 2011-02-09 | 2020-02-28 | 認知機能を改善するための方法および組成物 |
| JP2021131734A Pending JP2021175759A (ja) | 2011-02-09 | 2021-08-12 | 認知機能を改善するための方法および組成物 |
| JP2023119159A Withdrawn JP2023126654A (ja) | 2011-02-09 | 2023-07-21 | 認知機能を改善するための方法および組成物 |
| JP2025077648A Pending JP2025109773A (ja) | 2011-02-09 | 2025-05-07 | 認知機能を改善するための方法および組成物 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016132218A Withdrawn JP2016172772A (ja) | 2011-02-09 | 2016-07-04 | 認知機能を改善するための方法および組成物 |
| JP2018060195A Withdrawn JP2018100305A (ja) | 2011-02-09 | 2018-03-27 | 認知機能を改善するための方法および組成物 |
| JP2020033698A Pending JP2020079318A (ja) | 2011-02-09 | 2020-02-28 | 認知機能を改善するための方法および組成物 |
| JP2021131734A Pending JP2021175759A (ja) | 2011-02-09 | 2021-08-12 | 認知機能を改善するための方法および組成物 |
| JP2023119159A Withdrawn JP2023126654A (ja) | 2011-02-09 | 2023-07-21 | 認知機能を改善するための方法および組成物 |
| JP2025077648A Pending JP2025109773A (ja) | 2011-02-09 | 2025-05-07 | 認知機能を改善するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120214859A1 (https=) |
| EP (2) | EP2672822A4 (https=) |
| JP (7) | JP2014505108A (https=) |
| CN (2) | CN109662961A (https=) |
| AU (6) | AU2012214303A1 (https=) |
| BR (1) | BR112013020283A2 (https=) |
| CA (1) | CA2826765C (https=) |
| RU (1) | RU2665021C2 (https=) |
| WO (1) | WO2012109491A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018208662B2 (en) * | 2012-11-14 | 2020-07-23 | The Johns Hopkins University | Methods and Compositions for Treating Schizophrenia |
| US20140206667A1 (en) * | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US20160030391A1 (en) * | 2013-03-15 | 2016-02-04 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2014144663A1 (en) * | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| HUE053734T2 (hu) | 2014-01-21 | 2021-07-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk |
| KR20220049612A (ko) | 2014-01-21 | 2022-04-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| US20220354807A1 (en) * | 2019-09-30 | 2022-11-10 | Xiamen University | Use of valeric acid derivative in treatment of down's syndrome |
| WO2023183623A1 (en) | 2022-03-25 | 2023-09-28 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN115517682B (zh) * | 2022-11-25 | 2023-01-31 | 四川大学华西医院 | 基于胃肠电信号的认知功能障碍预测系统及构建方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US7090985B2 (en) * | 2002-12-03 | 2006-08-15 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| CN101027047A (zh) * | 2002-12-03 | 2007-08-29 | Ucb公司 | 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法 |
| JP2006516390A (ja) * | 2002-12-03 | 2006-07-06 | ユ セ ベ ソシエテ アノニム | 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法 |
| CN102166359A (zh) * | 2003-05-23 | 2011-08-31 | 大塚制药株式会社 | 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂 |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| JP5666087B2 (ja) * | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Ｃｎｓ関連疾患の治療のための方法及び組成物 |
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| KR20080030546A (ko) * | 2005-07-26 | 2008-04-04 | 유씨비 파마, 에스.에이. | 레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법 |
| EP1991212A1 (en) * | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| ES2444009T3 (es) * | 2006-06-08 | 2014-02-21 | Ucb Pharma, S.A. | Co-cristales de pirrolidinonas |
| WO2008062446A2 (en) * | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
| US20090176740A1 (en) * | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| EP2331088A4 (en) * | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES |
| DK3260118T3 (da) * | 2008-10-16 | 2021-04-19 | Univ Johns Hopkins | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| CN101647789B (zh) * | 2009-09-01 | 2011-08-17 | 天津药物研究院药业有限责任公司 | 左乙拉西坦缓释微丸胶囊制剂 |
| EA202092673A3 (ru) * | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| WO2014144663A1 (en) * | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
-
2012
- 2012-02-09 BR BR112013020283A patent/BR112013020283A2/pt not_active Application Discontinuation
- 2012-02-09 CN CN201811403097.5A patent/CN109662961A/zh active Pending
- 2012-02-09 WO PCT/US2012/024556 patent/WO2012109491A1/en not_active Ceased
- 2012-02-09 CA CA2826765A patent/CA2826765C/en active Active
- 2012-02-09 EP EP12744250.7A patent/EP2672822A4/en not_active Withdrawn
- 2012-02-09 JP JP2013553575A patent/JP2014505108A/ja not_active Withdrawn
- 2012-02-09 RU RU2013141155A patent/RU2665021C2/ru active
- 2012-02-09 AU AU2012214303A patent/AU2012214303A1/en not_active Abandoned
- 2012-02-09 US US13/370,253 patent/US20120214859A1/en not_active Abandoned
- 2012-02-09 CN CN201280014797XA patent/CN103476255A/zh active Pending
- 2012-02-09 EP EP18161109.6A patent/EP3400934A1/en not_active Ceased
-
2016
- 2016-04-27 AU AU2016202670A patent/AU2016202670A1/en not_active Abandoned
- 2016-07-04 JP JP2016132218A patent/JP2016172772A/ja not_active Withdrawn
-
2018
- 2018-02-22 AU AU2018201303A patent/AU2018201303A1/en not_active Abandoned
- 2018-03-27 JP JP2018060195A patent/JP2018100305A/ja not_active Withdrawn
-
2019
- 2019-11-19 AU AU2019268069A patent/AU2019268069A1/en not_active Ceased
-
2020
- 2020-02-28 JP JP2020033698A patent/JP2020079318A/ja active Pending
-
2021
- 2021-01-19 AU AU2021200325A patent/AU2021200325B2/en active Active
- 2021-08-12 JP JP2021131734A patent/JP2021175759A/ja active Pending
-
2022
- 2022-03-14 US US17/693,901 patent/US20230033195A1/en active Pending
- 2022-08-25 AU AU2022221492A patent/AU2022221492A1/en not_active Abandoned
-
2023
- 2023-07-21 JP JP2023119159A patent/JP2023126654A/ja not_active Withdrawn
-
2025
- 2025-05-07 JP JP2025077648A patent/JP2025109773A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505108A5 (https=) | ||
| JP2013518914A5 (https=) | ||
| JP2015528471A5 (https=) | ||
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2016517851A5 (https=) | ||
| JP2012505883A5 (https=) | ||
| WO2012125475A1 (en) | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases | |
| UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
| CA2893468C (en) | Use of vortioxetine and donepezil in the treatment of cognitive impairment | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| RU2013141155A (ru) | Способы и композиции для улучшения когнитивных функций | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| JP2016510343A5 (https=) | ||
| JP2016514688A5 (https=) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| JP2015522077A5 (https=) | ||
| JP2019518030A5 (https=) | ||
| JP2014534229A5 (https=) | ||
| JP2008540405A5 (https=) | ||
| US20250170147A1 (en) | Neuroactive steroids for treatment of gastrointestinal diseases or conditions | |
| JP2019516726A5 (https=) | ||
| JP2018531961A5 (https=) |